The ESMO-Magnitude of Clinical Benefit Scale uses a rational, structured and consistent approach to derive a relative ranking of the magnitude of clinically meaningful benefit that can be expected from anti-cancer treatments.
In 2015 ESMO launched the ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) to facilitate improved decision-making regarding the value of anti-cancer therapies, promote the accessibility and reduce iniquity of access to high value cancer treatments. In 2017, ESMO launched a revised version of the scale, ESMO-MCBS v 1.1.
The forms and instructions for both versions are freely accessible and downloadable.
The highest grade of the ESMO-MCBS is A in the curative setting and this is restricted to new curative treatments with a grade B also to be considered to trigger rapid reimbursement.
For non-curative indications 5 is the highest possible grade with 4 also to be considered to trigger rapid consideration for reimbursement.